ESTRO 2024 - Abstract Book

S101 ESTRO 2024 immunity, but this connection is not fully understood. Here, I will present our recent work on the hypothesis that abrogation of cell cycle checkpoints increases radiation-induced antitumor immune signaling. Specifically, we have looked at the impact of ATR inhibitors (VE822 and AZD6738) on type 1 interferon and immunogenic cell death signaling from irradiated human non-small-cell lung cancer (NSCLC) and osteosarcoma cells. Additionally, we have investigated the role of apoptotic caspases in regulating these effects. Furthermore, we have studied the effects of ATR (VE822) and ATM (AZD1390) inhibitors on type 1 interferon signaling in human glioblastoma cells, comparing X ray, proton and carbon-ion irradiation. Invited Speaker

3495

RTT perspective

Emma Hallam

Nottingham University Hospitals NHS Trust, Radiotherapy, Nottingham, United Kingdom

Abstract:

As ever more cancers are being cured, there is an ever-increasing need to provide support for patients living with and beyond their cancer diagnosis. Radiation induced fibrosis is an unintended consequence from radiotherapy treatment. This progressive, sclerotic disorder with varying clinical symptoms can stiffen connective tissue, compress peripheral nerve tracts contributing to diminished strength, flexibility and loss of function. Despite advances in planning and treatment delivery, this debilitating consequence leads to a reduced quality of life with poor physical and psychological function. It is estimated that by 2040 over 5 million people will be living with the consequences of cancer treatment. The Macmillan Nottingham Late Effects Clinic, the first of its kind within the UK is such a service that has for over a decade offered collaborative multi-disciplinary support throughout the survivorship trajectory. What has been clear since its evolution is that it is no longer acceptable to focus on acute toxicity and survival rates, as many patients are being cured but left with a reduced quality of life. To date over 1700 patients have been reviewed and offered supported self-management or specialist interventions to help manage and reduce the impact of these late effects, helping them to live with and beyond their cancer. The success of this service has been the effective management by the Therapeutic Radiographers and the prospective screening to identify consequences from treatment at an earlier time point using patient reported screening tools along with the use of novel treatments such as photobiomodulation therapy to manage this long-term condition.

3496

SBRT in oligometastatic colorectal cancer: When and what?

Marta Scorsetti

Humanitas Cancer Center, Radiotherapy and Radiosurgery, Milano, Italy